Medicine & Life Sciences
Anticoagulants
100%
Dabigatran
77%
SARS Virus
69%
Thrombin
62%
Rivaroxaban
57%
Hemostasis
39%
Heparin
37%
apixaban
32%
Prothrombin Time
30%
Factor Xa Inhibitors
28%
Activated Protein C Resistance
28%
Protein-Tyrosine Kinases
24%
Hemorrhage
23%
edoxaban
23%
Antibodies
20%
Coronavirus
19%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
19%
Partial Thromboplastin Time
19%
Low Molecular Weight Heparin
19%
Immunoglobulin G
18%
ponatinib
18%
Venous Thromboembolism
17%
Neutralizing Antibodies
16%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
15%
Atrial Fibrillation
15%
betrixaban
15%
Antithrombins
15%
Thrombosis
15%
Contraceptives, Oral, Combined
14%
Dasatinib
14%
Vitamin K
14%
Estetrol
13%
Meta-Analysis
13%
Thrombocytopenia
13%
Vaccines
13%
Severe Acute Respiratory Syndrome
13%
Systematic Reviews
12%
Thrombin Time
12%
Vaccination
12%
Warfarin
11%
ecarin
11%
Blood Platelets
11%
Thrombophilia
11%
Fibrinogen
10%
Prospective Studies
10%
Protein C
10%
Imatinib Mesylate
10%
Therapeutics
9%
drospirenone
9%
Chemical Compounds
Anticoagulant Agent
42%
Rivaroxaban
27%
Dabigatran
16%
Low Molecular Weight Heparin
15%
Dabigatran Etexilate
14%
Heparin
14%
Coagulation
14%
Protein C
11%
Plasma
11%
Thrombin
11%
Activated Partial Thromboplastin Time
10%
Anticoagulant
10%
Antagonist
10%
Prothrombin
8%
Thrombotic
8%
Drug
7%
Plasma Concentration
7%
Warfarin
7%
Dose
7%
Time
7%
Immunoassay
6%
Antithrombin
5%
Fondaparinux
5%
Contraceptive Agent
5%
D Dimer
5%
Viper Venom
5%